Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The name "phosphatidylinositol glycan anchor biosynthesis class P pseudogene 3" implies a pseudogene (a non-functional gene copy) that may be related to PIGP, which is an enzyme required for the biosynthesis of GPI anchors, structures that tether certain proteins to the cell membrane. However, "PIGPP3" is not described as a protein-coding gene, receptor, enzyme, or recognized therapeutic target. There is no evidence of function, disease association, or drug interaction in the literature or curated gene/protein databases (e.g., NCBI Gene, UniProt, GeneCards). If the intent was to refer to a functional member of the PIG gene family (e.g., PIGP), those are classified as enzymes involved in GPI anchor synthesis, but "PIGPP3" itself does not appear to exist as a validated biological entity. The gene "PIGPP3" appears to be incorrectly named or possibly a hypothetical/erroneous entry; it is best categorized as a pseudogene (if it exists at all), not a therapeutic target, and there is no credible evidence or data to suggest biological function, clinical utility, or relevance for drug discovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on phosphatidylinositol glycan anchor biosynthesis class P pseudogene 3 (PIGPP3).